OpenAI’s Biggest Week Wasn’t About ChatGPT

A model that could reshape drug discovery. A cyber variant built for defenders. And the week that proved AI has become genuinely dangerous territory - in ways than one. Last week, every major AI story came from one company. GPT-Rosalind - a purpose-built life sciences model - hit benchmarks that put it above the 95th percentile of human experts on novel biological data. GPT-5.4-Cyber gave vetted security professionals access to a model with the restrictions turned down. The Agents SDK got an overhaul that makes agentic infrastructure significantly easier to deploy.